References

1. Gorantla, S.; Rapalli, V.K.; Waghule, T.; Singh, P.P.; Dubey, S.K.; Saha, R.N.; Singhvi, G. Nanocarriers for Ocular Drug Delivery: Current Status and Translational Opportunity. RSC Adv. 2020, 10, 27835–27855. Urtti, A. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery. Adv. Drug Deliv. Rev. 2006, 58, 1131–1135. [Google Scholar] [CrossRef]
2. Cuenca, N.; Fernández-Sánchez, L.; Campello, L.; Maneu, V.; De la Villa, P.; Lax, P.; Pinilla, I. Cellular Responses Following Retinal Injuries and Therapeutic Approaches for Neurodegenerative Diseases. Prog. Retin. Eye Res. 2014, 43, 17–75. Akhter, M.H.; Ahmad, I.; Alshahrani, M.Y.; Al-Harbi, A.I.; Khalilullah, H.; Afzal, O.; Altamimi, A.S.A.; Najib Ullah, S.N.M.; Ojha, A.; Karim, S. Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System. Gels 2022, 8, 82. [Google Scholar] [CrossRef]
3. Arranz-Romera, A.; Esteban-Pérez, S.; Molina-Martínez, I.T.; Bravo-Osuna, I.; Herrero-Vanrell, R. Co-Delivery of Glial Cell-Derived Neurotrophic Factor (GDNF) and Tauroursodeoxycholic Acid (TUDCA) from PLGA Microspheres: Potential Combination Therapy for Retinal Diseases. Drug Deliv. Transl. Res. 2021, 11, 566–580. Addo, R.T. Ocular Drug Delivery: Advances, Challenges and Applications. In Ocular Drug Delivery: Advances, Challenges and Applications; Springer: Berlin/Heidelberg, Germany, 2016; pp. 1–185. [Google Scholar] [CrossRef]
4. Martín-Sabroso, C.; Fraguas-Sánchez, A.I.; Aparicio-Blanco, J.; Cano-Abad, M.F.; Torres-Suárez, A.I. Critical Attributes of Formulation and of Elaboration Process of PLGA-Protein Microparticles. Int. J. Pharm. 2015, 480, 27–36. Chang, A.Y.; Purt, B. Biochemistry, Tear Film. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
5. Sen, M.; Bassetto, M.; Poulhes, F.; Zelphati, O.; Ueffing, M.; Arango-Gonzalez, B. Efficient Ocular Delivery of VCP SiRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants. Pharmaceutics 2021, 13, 225. Bachu, R.D.; Chowdhury, P.; Al-Saedi, Z.H.F.; Karla, P.K.; Boddu, S.H.S. Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases. Pharmaceutics 2018, 10, 28. [Google Scholar] [CrossRef]
6. Sen, M.; Al-Amin, M.; Kicková, E.; Sadeghi, A.; Puranen, J.; Urtti, A.; Caliceti, P.; Salmaso, S.; Arango-Gonzalez, B.; Ueffing, M. Retinal Neuroprotection by Controlled Release of a VCP Inhibitor from Self-Assembled Nanoparticles. J. Control. Release 2021, 339, 307–320. Wu, K.Y.; Kulbay, M.; Tanasescu, C.; Jiao, B.; Nguyen, B.H.; Tran, S.D. An Overview of the Dry Eye Disease in Sjögren’s Syndrome Using Our Current Molecular Understanding. Int. J. Mol. Sci. 2023, 24, 1580. [Google Scholar] [CrossRef] [PubMed]
7. Platania, C.B.M.; Dei Cas, M.; Cianciolo, S.; Fidilio, A.; Lazzara, F.; Paroni, R.; Pignatello, R.; Strettoi, E.; Ghidoni, R.; Drago, F.; et al. Novel Ophthalmic Formulation of Myriocin: Implications in Retinitis Pigmentosa. Drug Deliv. 2019, 26, 237–243. Goel, M.; Picciani, R.G.; Lee, R.K.; Bhattacharya, S.K. Aqueous Humor Dynamics: A Review. Open Ophthalmol. J. 2010, 4, 52–59. [Google Scholar] [CrossRef] [PubMed]
8. Strettoi, E.; Gargini, C.; Novelli, E.; Sala, G.; Piano, I.; Gasco, P.; Ghidoni, R. Inhibition of Ceramide Biosynthesis Preserves Photoreceptor Structure and Function in a Mouse Model of Retinitis Pigmentosa. Proc. Natl. Acad. Sci. USA 2010, 107, 18706–18711. Chen, M.-S.; Hou, P.-K.; Tai, T.-Y.; Lin, B.J. Blood-Ocular Barriers. Tzu Chi Med. J. 2008, 20, 25–34. [Google Scholar] [CrossRef]
9. Xia, W.; Li, C.; Chen, Q.; Huang, J.; Zhao, Z.; Liu, P.; Xu, K.; Li, L.; Hu, F.; Zhang, S.; et al. Intravenous Route to Choroidal Neovascularization by Macrophage-Disguised Nanocarriers for MTOR Modulation. Acta Pharm. Sin. B 2022, 12, 2506–2521. Cunha-Vaz, J.; Bernardes, R.; Lobo, C. Blood-Retinal Barrier. Eur. J. Ophthalmol. 2011, 21, 3–9. [Google Scholar] [CrossRef] [PubMed]
10. Mei, L.; Yu, M.; Liu, Y.; Weh, E.; Pawar, M.; Li, L.; Besirli, C.G.; Schwendeman, A.A. Synthetic High-Density Lipoprotein Nanoparticles Delivering Rapamycin for the Treatment of Age-Related Macular Degeneration. Nanomedicine 2022, 44, 102571. Bertens, C.J.F.; Gijs, M.; van den Biggelaar, F.J.H.M.; Nuijts, R.M.M.A. Topical Drug Delivery Devices: A Review. Exp. Eye Res. 2018, 168, 149–160. [Google Scholar] [CrossRef] [PubMed]
11. Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results. Ophthalmology 2020, 127, S135–S145. Singh Malik, D.; Mital, N.; Kaur, G. Topical Drug Delivery Systems: A Patent Review. Expert Opin. Ther. Pat. 2016, 26, 213–228. [Google Scholar] [CrossRef]
12. Feng, L.; Ju, M.; Lee, K.Y.V.; Mackey, A.; Evangelista, M.; Iwata, D.; Adamson, P.; Lashkari, K.; Foxton, R.; Shima, D.; et al. A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. Am. J. Pathol. 2017, 187, 2208–2221. Farkouh, A.; Frigo, P.; Czejka, M. Systemic Side Effects of Eye Drops: A Pharmacokinetic Perspective. Clin. Ophthalmol. 2016, 10, 2433–2441. [Google Scholar] [CrossRef]
13. Zhang, L.; Yan, J.J.; Wang, H.Y.; Li, M.Q.; Wang, X.X.; Fan, L.; Wang, Y.S. A Trojan Horse Biomimetic Delivery System Using Mesenchymal Stem Cells for HIF-1α SiRNA-Loaded Nanoparticles on Retinal Pigment Epithelial Cells under Hypoxia Environment. Int. J. Ophthalmol. 2022, 15, 1743–1751. Wu, W.; He, Z.; Zhang, Z.; Yu, X.; Song, Z.; Li, X. Intravitreal Injection of Rapamycin-Loaded Polymeric Micelles for Inhibition of Ocular Inflammation in Rat Model. Int. J. Pharm. 2016, 513, 238–246. [Google Scholar] [CrossRef] [PubMed]
14. Kimbrel, E.A.; Lanza, R. Next-Generation Stem Cells—Ushering in a New Era of Cell-Based Therapies. Nat. Rev. Drug Discov. 2020, 19, 463–479. Abrishami, M.; Shariati, M.M.; Malaekeh-Nikouei, B.; Tajani, A.S.; Mahmoudi, A.; Abrishami, M.; Khameneh, B. Preparation and in Vivo Evaluation of Nanoliposomes Containing Vancomycin after Intravitreal Injection in Albino Rabbits. Iran. J. Basic Med. Sci. 2020, 23, 551–555. [Google Scholar] [CrossRef] [PubMed]
15. Nguyen, D.D.; Luo, L.J.; Yang, C.J.; Lai, J.Y. Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration. ACS Nano 2023, 17, 168–183. García-Caballero, C.; Prieto-Calvo, E.; Checa-Casalengua, P.; García-Martín, E.; Polo-Llorens, V.; García-Feijoo, J.; Molina-Martínez, I.T.; Bravo-Osuna, I.; Herrero-Vanrell, R. Six Month Delivery of GDNF from PLGA/Vitamin E Biodegradable Microspheres after Intravitreal Injection in Rabbits. Eur. J. Pharm. Sci. 2017, 103, 19–26. [Google Scholar] [CrossRef]
16. Lai, S.; Wei, Y.; Wu, Q.; Zhou, K.; Liu, T.; Zhang, Y.; Jiang, N.; Xiao, W.; Chen, J.; Liu, Q.; et al. Liposomes for Effective Drug Delivery to the Ocular Posterior Chamber. J. Nanobiotechnol. 2019, 17, 64. Park, J.G.; Callaway, N.F.; Ludwig, C.A.; Mahajan, V.B. Intravitreal Methotrexate and Fluocinolone Acetonide Implantation for Vogt-Koyanagi-Harada Uveitis. Am. J. Ophthalmol. Case Rep. 2020, 19, 100859. [Google Scholar] [CrossRef] [PubMed]
17. Oshitari, T. Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy. Int. J. Environ. Res. Public Health 2021, 19, 439. Glendenning, A.; Crews, K.; Sturdivant, J.; deLong, M.A.; Kopczynski, C.; Lin, C.-W. Sustained Release, Biodegradable PEA Implants for Intravitreal Delivery of the ROCK/PKC Inhibitor AR-13503. Investig. Ophthalmol. Vis. Sci. 2018, 59, 5672. [Google Scholar]
18. Zeng, L.; Ma, W.; Shi, L.; Chen, X.; Wu, R.; Zhang, Y.; Chen, H.; Chen, H. Poly(Lactic-Co-Glycolic Acid) Nanoparticle-Mediated Interleukin-12 Delivery for the Treatment of Diabetic Retinopathy. Int. J. Nanomed. 2019, 14, 6357–6369. Blazaki, S.; Pachis, K.; Tzatzarakis, M.; Tsilimbaris, M.; Antimisiaris, S.G. Novel Liposome Aggregate Platform (LAP) System for Sustained Retention of Drugs in the Posterior Ocular Segment Following Intravitreal Injection. Int. J. Pharm. 2020, 576, 118987. [Google Scholar] [CrossRef]
19. Romeo, A.; Bonaccorso, A.; Carbone, C.; Lupo, G.; Daniela Anfuso, C.; Giurdanella, G.; Caggia, C.; Randazzo, C.; Russo, N.; Luca Romano, G.; et al. Melatonin Loaded Hybrid Nanomedicine: DoE Approach, Optimization and in Vitro Study on Diabetic Retinopathy Model. Int. J. Pharm. 2022, 627, 122195. Agban, Y.; Thakur, S.S.; Mugisho, O.O.; Rupenthal, I.D. Depot Formulations to Sustain Periocular Drug Delivery to the Posterior Eye Segment. Drug Discov. Today 2019, 24, 1458–1469. [Google Scholar] [CrossRef]
20. Zingale, E.; Rizzo, S.; Bonaccorso, A.; Consoli, V.; Vanella, L.; Musumeci, T.; Spadaro, A.; Pignatello, R. Optimization of Lipid Nanoparticles by Response Surface Methodology to Improve the Ocular Delivery of Diosmin: Characterization and In-Vitro Anti-Inflammatory Assessment. Pharmaceutics 2022, 14, 1961. Radhakrishnan, K.; Vincent, A.; Joseph, R.R.; Moreno, M.; Dickescheid, A.; Agrawal, R.; Venkatraman, S. Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein. Pharmaceutics 2019, 11, 330. [Google Scholar] [CrossRef]
21. Chauhan, I.; Yasir, M.; Verma, M.; Singh, A.P. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv. Pharm. Bull. 2020, 10, 150–165. Yiu, G.; Chung, S.H.; Mollhoff, I.N.; Nguyen, U.T.; Thomasy, S.M.; Yoo, J.; Taraborelli, D.; Noronha, G. Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates. Mol. Ther. Methods Clin. Dev. 2020, 16, 179–191. [Google Scholar] [CrossRef]
22. Müller, R.H.; Shegokar, R.; Keck, C.M. 20 Years of Lipid Nanoparticles (SLN and NLC): Present State of Development and Industrial Applications. Curr. Drug Discov. Technol. 2011, 8, 207–227. Weijtens, O.; Feron, E.J.; Schoemaker, R.C.; Cohen, A.F.; Lentjes, E.G.W.M.; Romijn, F.P.H.T.M.; Van Meurs, J.C. High Concentration of Dexamethasone in Aqueous and Vitreous after Subconjunctival Injection. Am. J. Ophthalmol. 1999, 128, 192–197. [Google Scholar] [CrossRef]
23. Radwan, S.E.S.; El-Kamel, A.; Zaki, E.I.; Burgalassi, S.; Zucchetti, E.; El-Moslemany, R.M. Hyaluronic-Coated Albumin Nanoparticles for the Non-Invasive Delivery of Apatinib in Diabetic Retinopathy. Int. J. Nanomed. 2021, 16, 4481–4494. Salama, H.A.; Ghorab, M.; Mahmoud, A.A.; Abdel Hady, M. PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma. AAPS PharmSciTech 2017, 18, 2517–2528. [Google Scholar] [CrossRef] [PubMed]
24. Mahaling, B.; Srinivasarao, D.A.; Raghu, G.; Kasam, R.K.; Bhanuprakash Reddy, G.; Katti, D.S. A Non-Invasive Nanoparticle Mediated Delivery of Triamcinolone Acetonide Ameliorates Diabetic Retinopathy in Rats. Nanoscale 2018, 10, 16485–16498. Fu, J.; Sun, F.; Liu, W.; Liu, Y.; Gedam, M.; Hu, Q.; Fridley, C.; Quigley, H.A.; Hanes, J.; Pitha, I. Subconjunctival Delivery of Dorzolamide-Loaded Poly(Ether-Anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits. Mol. Pharm. 2016, 13, 2987–2995. [Google Scholar] [CrossRef] [PubMed]
25. Tang, B.C.; Dawson, M.; Lai, S.K.; Wang, Y.Y.; Suk, J.S.; Yang, M.; Zeitlin, P.; Boyle, M.P.; Fu, J.; Hanes, J. Biodegradable Polymer Nanoparticles That Rapidly Penetrate the Human Mucus Barrier. Proc. Natl. Acad. Sci. USA 2009, 106, 19268–19273. Cuming, R.S.; Abarca, E.M.; Duran, S.; Wooldridge, A.A.; Stewart, A.J.; Ravis, W.; Babu, R.J.; Lin, Y.J.; Hathcock, T. Development of a Sustained-Release Voriconazole-Containing Thermogel for Subconjunctival Injection in Horses. Investig. Ophthalmol. Vis. Sci. 2017, 58, 2746–2754. [Google Scholar] [CrossRef] [PubMed]
26. Navarro-Partida, J.; Altamirano-Vallejo, J.C.; la Rosa, A.G.D.; Armendariz-Borunda, J.; Castro-Castaneda, C.R.; Santos, A. Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. Pharmaceutics 2021, 13, 322. Martínez-Carrasco, R.; Sánchez-Abarca, L.I.; Nieto-Gómez, C.; Martín García, E.; Sánchez-Guijo, F.; Argüeso, P.; Aijón, J.; Hernández-Galilea, E.; Velasco, A. Subconjunctival Injection of Mesenchymal Stromal Cells Protects the Cornea in an Experimental Model of GVHD. Ocul. Surf. 2019, 17, 285–294. [Google Scholar] [CrossRef] [PubMed]
27. Chan, C.K.M.; Fan, D.S.P.; Chan, W.M.; Lai, W.W.; Lee, V.Y.W.; Lam, D.S.C. Ocular-Hypertensive Response and Corneal Endothelial Changes after Intravitreal Triamcinolone Injections in Chinese Subjects: A 6-Month Follow-up Study. Eye 2005, 19, 625–630. Lindholm, J.M.; Taipale, C.; Ylinen, P.; Tuuminen, R. Perioperative Subconjunctival Triamcinolone Acetonide Injection for Prevention of Inflammation and Macular Oedema after Cataract Surgery. Acta Ophthalmol. 2020, 98, 36–42. [Google Scholar] [CrossRef]
28. Khalil, M.; Hashmi, U.; Riaz, R.; Rukh Abbas, S. Chitosan Coated Liposomes (CCL) Containing Triamcinolone Acetonide for Sustained Delivery: A Potential Topical Treatment for Posterior Segment Diseases. Int. J. Biol. Macromol. 2020, 143, 483–491. Schneider, M.E.; Milstein, D.E.; Oyakawa, R.T.; Ober, R.R.; Campo, R. Ocular Perforation from a Retrobulbar Injection. Am. J. Ophthalmol. 1988, 106, 35–40. [Google Scholar] [CrossRef]
29. Safi, M.; Ang, M.J.; Patel, P.; Silkiss, R.Z. Rhino-Orbital-Cerebral Mucormycosis (ROCM) and Associated Cerebritis Treated with Adjuvant Retrobulbar Amphotericin B. Am. J. Ophthalmol. Case Rep. 2020, 19, 100771. [Google Scholar] [CrossRef]
30. Arbisser, L.B. Safety of Intracameral Moxifloxacin for Prophylaxis of Endophthalmitis after Cataract Surgery. J. Cataract. Refract. Surg. 2008, 34, 1114–1120. [Google Scholar] [CrossRef]
31. Christopher, K.; Chauhan, A. Contact Lens Based Drug Delivery to the Posterior Segment Via Iontophoresis in Cadaver Rabbit Eyes. Pharm. Res. 2019, 36. [Google Scholar] [CrossRef]
32. Jung, J.H.; Chiang, B.; Grossniklaus, H.E.; Prausnitz, M.R. Ocular Drug Delivery Targeted by Iontophoresis in the Suprachoroidal Space Using a Microneedle. J. Control. Release 2018, 277, 14–22. [Google Scholar] [CrossRef]
33. See, G.L.; Sagesaka, A.; Torizuka, H.; Todo, H.; Sugibayashi, K. Iontophoresis-Aided Drug Delivery into the Eyeball via Eyelid Skin. J. Drug Deliv. Sci. Technol. 2018, 47, 380–385. [Google Scholar] [CrossRef]
34. dos Santos, G.A.; Ferreira-Nunes, R.; Dalmolin, L.F.; dos Santos Ré, A.C.; Anjos, J.L.V.; Mendanha, S.A.; Aires, C.P.; Lopez, R.F.V.; Cunha-Filho, M.; Gelfuso, G.M.; et al. Besifloxacin Liposomes with Positively Charged Additives for an Improved Topical Ocular Delivery. Sci. Rep. 2020, 10, 19285. [Google Scholar] [CrossRef] [PubMed]
35. Habot-Wilner, Z.; Noronha, G.; Wykoff, C.C. Suprachoroidally Injected Pharmacological Agents for the Treatment of Chorio-Retinal Diseases: A Targeted Approach. Acta Ophthalmol. 2019, 97, 460–472. [Google Scholar] [CrossRef]
36. Allyn, M.M.; Luo, R.H.; Hellwarth, E.B.; Swindle-Reilly, K.E. Considerations for Polymers Used in Ocular Drug Delivery. Front. Med. 2022, 8, 787644. [Google Scholar] [CrossRef]
37. Bodratti, A.M.; Alexandridis, P. Amphiphilic Block Copolymers in Drug Delivery: Advances in Formulation Structure and Performance. Expert. Opin. Drug Deliv. 2018, 15, 1085–1104. [Google Scholar] [CrossRef] [PubMed]
38. Liu, W.; Borrell, M.A.; Venerus, D.C.; Mieler, W.F.; Kang-Mieler, J.J. Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab. Transl. Vis. Sci. Technol. 2019, 8, 12. [Google Scholar] [CrossRef]
39. Zhang, X.; Wei, D.; Xu, Y.; Zhu, Q. Hyaluronic Acid in Ocular Drug Delivery. Carbohydr. Polym. 2021, 264, 118006. [Google Scholar] [CrossRef]
40. Orasugh, J.T.; Dutta, S.; Das, D.; Nath, J.; Pal, C.; Chattopadhyay, D. Utilization of Cellulose Nanocrystals (CNC) Biopolymer Nanocomposites in Ophthalmic Drug Delivery System (ODDS). J. Nanotechnol. Res. 2019, 1, 75–87. [Google Scholar]
41. Gupta, B.; Mishra, V.; Gharat, S.; Momin, M.; Omri, A. Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems. Pharmaceuticals 2021, 14, 1201. [Google Scholar] [CrossRef]
42. Tavakolian, M.; Jafari, S.M.; van de Ven, T.G.M. A Review on Surface-Functionalized Cellulosic Nanostructures as Biocompatible Antibacterial Materials. Nanomicro Lett. 2020, 12, 73. [Google Scholar] [CrossRef]
43. Junnuthula, V.; Boroujeni, A.S.; Cao, S.; Tavakoli, S.; Ridolfo, R.; Toropainen, E.; Ruponen, M.; van Hest, J.C.M.; Urtti, A. Intravitreal Polymeric Nanocarriers with Long Ocular Retention and Targeted Delivery to the Retina and Optic Nerve Head Region. Pharmaceutics 2021, 13, 445. [Google Scholar] [CrossRef] [PubMed]
44. Kianersi, S.; Solouk, A.; Saber-Samandari, S.; Keshel, S.H.; Pasbakhsh, P. Alginate Nanoparticles as Ocular Drug Delivery Carriers. J. Drug Deliv. Sci. Technol. 2021, 66, 102889. [Google Scholar] [CrossRef]
45. Wong, F.S.Y.; Tsang, K.K.; Chu, A.M.W.; Chan, B.P.; Yao, K.M.; Lo, A.C.Y. Injectable Cell-Encapsulating Composite Alginate-Collagen Platform with Inducible Termination Switch for Safer Ocular Drug Delivery. Biomaterials 2019, 201, 53–67. [Google Scholar] [CrossRef] [PubMed]
46. Jiang, G.; Jia, H.; Qiu, J.; Mo, Z.; Wen, Y.; Zhang, Y.; Wen, Y.; Xie, Q.; Ban, J.; Lu, Z.; et al. PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers. Int. J. Nanomed. 2020, 15, 9373–9387. [Google Scholar] [CrossRef] [PubMed]
47. Swetledge, S.; Carter, R.; Stout, R.; Astete, C.E.; Jung, J.P.; Sabliov, C.M. Stability and Ocular Biodistribution of Topically Administered PLGA Nanoparticles. Sci. Rep. 2021, 11, 12270. [Google Scholar] [CrossRef]
48. Weng, Y.H.; Ma, X.W.; Che, J.; Li, C.; Liu, J.; Chen, S.Z.; Wang, Y.Q.; Gan, Y.L.; Chen, H.; Hu, Z.B.; et al. Nanomicelle-Assisted Targeted Ocular Delivery with Enhanced Antiinflammatory Efficacy In Vivo. Adv. Sci. 2017, 5, 1700455. [Google Scholar] [CrossRef]
49. Dai, L.; Li, X.; Yao, M.; Niu, P.; Yuan, X.; Li, K.; Chen, M.; Fu, Z.; Duan, X.; Liu, H.; et al. Programmable Prodrug Micelle with Size-Shrinkage and Charge-Reversal for Chemotherapy-Improved IDO Immunotherapy. Biomaterials 2020, 241, 119901. [Google Scholar] [CrossRef]
50. Hwang, D.; Ramsey, J.D.; Kabanov, A.V. Polymeric Micelles for the Delivery of Poorly Soluble Drugs: From Nanoformulation to Clinical Approval. Adv. Drug Deliv. Rev. 2020, 156, 80–118. [Google Scholar] [CrossRef] [PubMed]
51. Sun, H.; Meng, F.; Cheng, R.; Deng, C.; Zhong, Z. Reduction-Responsive Polymeric Micelles and Vesicles for Triggered Intracellular Drug Release. Antioxid. Redox Signal. 2014, 21, 755–767. [Google Scholar] [CrossRef] [PubMed]
52. Yu, Y.; Chen, D.; Li, Y.; Yang, W.; Tu, J.; Shen, Y. Improving the Topical Ocular Pharmacokinetics of Lyophilized Cyclosporine A-Loaded Micelles: Formulation, in Vitro and in Vivo Studies. Drug Deliv. 2018, 25, 888–899. [Google Scholar] [CrossRef]
53. Xu, X.; Sun, L.; Zhou, L.; Cheng, Y.; Cao, F. Functional Chitosan Oligosaccharide Nanomicelles for Topical Ocular Drug Delivery of Dexamethasone. Carbohydr. Polym. 2020, 227, 115356. [Google Scholar] [CrossRef] [PubMed]
54. Lai, S.; Wei, Y.; Wu, Q.; Zhou, K.; Liu, T.; Zhang, Y.; Jiang, N.; Xiao, W.; Chen, J.; Liu, Q.; et al. Liposomes for Effective Drug Delivery to the Ocular Posterior Chamber. J. Nanobiotechnol. 2019, 17, 64. [Google Scholar] [CrossRef] [PubMed]
55. Abdi, F.; Arkan, E.; Mansouri, K.; Shekarbeygi, Z.; Barzegari, E. Interactions of Bevacizumab with Chitosan Biopolymer Nanoparticles: Molecular Modeling and Spectroscopic Study. J. Mol. Liq. 2021, 339, 116655. [Google Scholar] [CrossRef]
56. Ishida, T.; Harashima, H.; Kiwada, H. Liposome Clearance. Biosci. Rep. 2002, 22, 197–224. [Google Scholar] [CrossRef] [PubMed]
57. Jin, X.; Zhu, L.; Xue, B.; Zhu, X.; Yan, D. Supramolecular Nanoscale Drug-Delivery System with Ordered Structure. Natl. Sci. Rev. 2019, 6, 1128–1137. [Google Scholar] [CrossRef] [PubMed]
58. Ji, T.; Kohane, D.S. Nanoscale Systems for Local Drug Delivery. Nano Today 2019, 28, 100765. [Google Scholar] [CrossRef]
59. Di, J.; Gao, X.; Du, Y.; Zhang, H.; Gao, J.; Zheng, A. Size, Shape, Charge and “Stealthy” Surface: Carrier Properties Affect the Drug Circulation Time in Vivo. Asian J. Pharm. Sci. 2021, 16, 444–458. [Google Scholar] [CrossRef]
60. Rebibo, L.; Tam, C.; Sun, Y.; Shoshani, E.; Badihi, A.; Nassar, T.; Benita, S. Topical Tacrolimus Nanocapsules Eye Drops for Therapeutic Effect Enhancement in Both Anterior and Posterior Ocular Inflammation Models. J. Control. Release 2021, 333, 283–297. [Google Scholar] [CrossRef]
61. Duan, Y.; Dhar, A.; Patel, C.; Khimani, M.; Neogi, S.; Sharma, P.; Siva Kumar, N.; Vekariya, R.L. A Brief Review on Solid Lipid Nanoparticles: Part and Parcel of Contemporary Drug Delivery Systems. RSC Adv. 2020, 10, 26777–26791. [Google Scholar] [CrossRef]
62. Lancina, M.G.; Yang, H. Dendrimers for Ocular Drug Delivery. Can. J. Chem. 2017, 95, 897–902. [Google Scholar] [CrossRef]
63. Lin, D.; Lei, L.; Shi, S.; Li, X. Stimulus-Responsive Hydrogel for Ophthalmic Drug Delivery. Macromol. Biosci. 2019, 19, e1900001. [Google Scholar] [CrossRef] [PubMed]
64. Lynch, C.R.; Kondiah, P.P.D.; Choonara, Y.E.; du Toit, L.C.; Ally, N.; Pillay, V. Hydrogel Biomaterials for Application in Ocular Drug Delivery. Front. Bioeng. Biotechnol. 2020, 8, 228. [Google Scholar] [CrossRef] [PubMed]
65. Nagai, N.; Otake, H. Novel Drug Delivery Systems for the Management of Dry Eye. Adv. Drug Deliv. Rev. 2022, 191, 114582. [Google Scholar] [CrossRef] [PubMed]
66. Jacob, S.; Nair, A.B.; Shah, J. Emerging Role of Nanosuspensions in Drug Delivery Systems. Biomater. Res. 2020, 24, 3. [Google Scholar] [CrossRef]
67. Xie, J.; Luo, Y.; Liu, Y.; Ma, Y.; Yue, P.; Yang, M. Novel Redispersible Nanosuspensions Stabilized by Co-Processed Nanocrystalline Cellulose-Sodium Carboxymethyl Starch for Enhancing Dissolution and Oral Bioavailability of Baicalin. Int. J. Nanomed. 2019, 14, 353–369. [Google Scholar] [CrossRef]
68. Gade, S.S.; Pentlavalli, S.; Mishra, D.; Vora, L.K.; Waite, D.; Alvarez-Lorenzo, C.I.; Herrero Vanrell, M.R.; Laverty, G.; Larraneta, E.; Donnelly, R.F.; et al. Injectable Depot Forming Thermoresponsive Hydrogel for Sustained Intrascleral Delivery of Sunitinib Using Hollow Microneedles. J. Ocul. Pharmacol. Ther. 2022, 38, 433–448. [Google Scholar] [CrossRef]
69. Gorantla, S.; Rapalli, V.K.; Waghule, T.; Singh, P.P.; Dubey, S.K.; Saha, R.N.; Singhvi, G. Nanocarriers for Ocular Drug Delivery: Current Status and Translational Opportunity. RSC Adv. 2020, 10, 27835–27855. [Google Scholar] [CrossRef]
70. Cuenca, N.; Fernández-Sánchez, L.; Campello, L.; Maneu, V.; De la Villa, P.; Lax, P.; Pinilla, I. Cellular Responses Following Retinal Injuries and Therapeutic Approaches for Neurodegenerative Diseases. Prog. Retin. Eye Res. 2014, 43, 17–75. [Google Scholar] [CrossRef]
71. Arranz-Romera, A.; Esteban-Pérez, S.; Molina-Martínez, I.T.; Bravo-Osuna, I.; Herrero-Vanrell, R. Co-Delivery of Glial Cell-Derived Neurotrophic Factor (GDNF) and Tauroursodeoxycholic Acid (TUDCA) from PLGA Microspheres: Potential Combination Therapy for Retinal Diseases. Drug Deliv. Transl. Res. 2021, 11, 566–580. [Google Scholar] [CrossRef]
72. Martín-Sabroso, C.; Fraguas-Sánchez, A.I.; Aparicio-Blanco, J.; Cano-Abad, M.F.; Torres-Suárez, A.I. Critical Attributes of Formulation and of Elaboration Process of PLGA-Protein Microparticles. Int. J. Pharm. 2015, 480, 27–36. [Google Scholar] [CrossRef]
73. Sen, M.; Bassetto, M.; Poulhes, F.; Zelphati, O.; Ueffing, M.; Arango-Gonzalez, B. Efficient Ocular Delivery of VCP SiRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants. Pharmaceutics 2021, 13, 225. [Google Scholar] [CrossRef] [PubMed]
74. Sen, M.; Al-Amin, M.; Kicková, E.; Sadeghi, A.; Puranen, J.; Urtti, A.; Caliceti, P.; Salmaso, S.; Arango-Gonzalez, B.; Ueffing, M. Retinal Neuroprotection by Controlled Release of a VCP Inhibitor from Self-Assembled Nanoparticles. J. Control. Release 2021, 339, 307–320. [Google Scholar] [CrossRef] [PubMed]
75. Platania, C.B.M.; Dei Cas, M.; Cianciolo, S.; Fidilio, A.; Lazzara, F.; Paroni, R.; Pignatello, R.; Strettoi, E.; Ghidoni, R.; Drago, F.; et al. Novel Ophthalmic Formulation of Myriocin: Implications in Retinitis Pigmentosa. Drug Deliv. 2019, 26, 237–243. [Google Scholar] [CrossRef]
76. Strettoi, E.; Gargini, C.; Novelli, E.; Sala, G.; Piano, I.; Gasco, P.; Ghidoni, R. Inhibition of Ceramide Biosynthesis Preserves Photoreceptor Structure and Function in a Mouse Model of Retinitis Pigmentosa. Proc. Natl. Acad. Sci. USA 2010, 107, 18706–18711. [Google Scholar] [CrossRef] [PubMed]
77. Xia, W.; Li, C.; Chen, Q.; Huang, J.; Zhao, Z.; Liu, P.; Xu, K.; Li, L.; Hu, F.; Zhang, S.; et al. Intravenous Route to Choroidal Neovascularization by Macrophage-Disguised Nanocarriers for MTOR Modulation. Acta Pharm. Sin. B 2022, 12, 2506–2521. [Google Scholar] [CrossRef] [PubMed]
78. Mei, L.; Yu, M.; Liu, Y.; Weh, E.; Pawar, M.; Li, L.; Besirli, C.G.; Schwendeman, A.A. Synthetic High-Density Lipoprotein Nanoparticles Delivering Rapamycin for the Treatment of Age-Related Macular Degeneration. Nanomedicine 2022, 44, 102571. [Google Scholar] [CrossRef]
79. Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results. Ophthalmology 2020, 127, S135–S145. [Google Scholar] [CrossRef]
80. Feng, L.; Ju, M.; Lee, K.Y.V.; Mackey, A.; Evangelista, M.; Iwata, D.; Adamson, P.; Lashkari, K.; Foxton, R.; Shima, D.; et al. A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. Am. J. Pathol. 2017, 187, 2208–2221. [Google Scholar] [CrossRef]
81. Zhang, L.; Yan, J.J.; Wang, H.Y.; Li, M.Q.; Wang, X.X.; Fan, L.; Wang, Y.S. A Trojan Horse Biomimetic Delivery System Using Mesenchymal Stem Cells for HIF-1α SiRNA-Loaded Nanoparticles on Retinal Pigment Epithelial Cells under Hypoxia Environment. Int. J. Ophthalmol. 2022, 15, 1743–1751. [Google Scholar] [CrossRef]
82. Kimbrel, E.A.; Lanza, R. Next-Generation Stem Cells—Ushering in a New Era of Cell-Based Therapies. Nat. Rev. Drug Discov. 2020, 19, 463–479. [Google Scholar] [CrossRef]
83. Nguyen, D.D.; Luo, L.J.; Yang, C.J.; Lai, J.Y. Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration. ACS Nano 2023, 17, 168–183. [Google Scholar] [CrossRef]
84. Oshitari, T. Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy. Int. J. Environ. Res. Public Health 2021, 19, 439. [Google Scholar] [CrossRef]
85. Zeng, L.; Ma, W.; Shi, L.; Chen, X.; Wu, R.; Zhang, Y.; Chen, H.; Chen, H. Poly(Lactic-Co-Glycolic Acid) Nanoparticle-Mediated Interleukin-12 Delivery for the Treatment of Diabetic Retinopathy. Int. J. Nanomed. 2019, 14, 6357–6369. [Google Scholar] [CrossRef]
86. Romeo, A.; Bonaccorso, A.; Carbone, C.; Lupo, G.; Daniela Anfuso, C.; Giurdanella, G.; Caggia, C.; Randazzo, C.; Russo, N.; Luca Romano, G.; et al. Melatonin Loaded Hybrid Nanomedicine: DoE Approach, Optimization and in Vitro Study on Diabetic Retinopathy Model. Int. J. Pharm. 2022, 627, 122195. [Google Scholar] [CrossRef]
87. Zingale, E.; Rizzo, S.; Bonaccorso, A.; Consoli, V.; Vanella, L.; Musumeci, T.; Spadaro, A.; Pignatello, R. Optimization of Lipid Nanoparticles by Response Surface Methodology to Improve the Ocular Delivery of Diosmin: Characterization and In-Vitro Anti-Inflammatory Assessment. Pharmaceutics 2022, 14, 1961. [Google Scholar] [CrossRef]
88. Chauhan, I.; Yasir, M.; Verma, M.; Singh, A.P. Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery. Adv. Pharm. Bull. 2020, 10, 150–165. [Google Scholar] [CrossRef]
89. Müller, R.H.; Shegokar, R.; Keck, C.M. 20 Years of Lipid Nanoparticles (SLN and NLC): Present State of Development and Industrial Applications. Curr. Drug Discov. Technol. 2011, 8, 207–227. [Google Scholar] [CrossRef] [PubMed]
90. Radwan, S.E.S.; El-Kamel, A.; Zaki, E.I.; Burgalassi, S.; Zucchetti, E.; El-Moslemany, R.M. Hyaluronic-Coated Albumin Nanoparticles for the Non-Invasive Delivery of Apatinib in Diabetic Retinopathy. Int. J. Nanomed. 2021, 16, 4481–4494. [Google Scholar] [CrossRef]
91. Mahaling, B.; Srinivasarao, D.A.; Raghu, G.; Kasam, R.K.; Bhanuprakash Reddy, G.; Katti, D.S. A Non-Invasive Nanoparticle Mediated Delivery of Triamcinolone Acetonide Ameliorates Diabetic Retinopathy in Rats. Nanoscale 2018, 10, 16485–16498. [Google Scholar] [CrossRef] [PubMed]
92. Tang, B.C.; Dawson, M.; Lai, S.K.; Wang, Y.Y.; Suk, J.S.; Yang, M.; Zeitlin, P.; Boyle, M.P.; Fu, J.; Hanes, J. Biodegradable Polymer Nanoparticles That Rapidly Penetrate the Human Mucus Barrier. Proc. Natl. Acad. Sci. USA 2009, 106, 19268–19273. [Google Scholar] [CrossRef] [PubMed]
93. Navarro-Partida, J.; Altamirano-Vallejo, J.C.; la Rosa, A.G.D.; Armendariz-Borunda, J.; Castro-Castaneda, C.R.; Santos, A. Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. Pharmaceutics 2021, 13, 322. [Google Scholar] [CrossRef] [PubMed]
94. Chan, C.K.M.; Fan, D.S.P.; Chan, W.M.; Lai, W.W.; Lee, V.Y.W.; Lam, D.S.C. Ocular-Hypertensive Response and Corneal Endothelial Changes after Intravitreal Triamcinolone Injections in Chinese Subjects: A 6-Month Follow-up Study. Eye 2005, 19, 625–630. [Google Scholar] [CrossRef] [PubMed]
95. Khalil, M.; Hashmi, U.; Riaz, R.; Rukh Abbas, S. Chitosan Coated Liposomes (CCL) Containing Triamcinolone Acetonide for Sustained Delivery: A Potential Topical Treatment for Posterior Segment Diseases. Int. J. Biol. Macromol. 2020, 143, 483–491. [Google Scholar] [CrossRef]
96. Alambiaga-Caravaca, A.M.; Domenech-Monsell, I.M.; Sebastián-Morelló, M.; Calatayud-Pascual, M.A.; Merino, V.; Rodilla, V.; López-Castellano, A. Development, Characterization, and Ex Vivo Evaluation of an Insert for the Ocular Administration of Progesterone. Int. J. Pharm. 2021, 606, 120921. [Google Scholar] [CrossRef] [PubMed]
97. Yadav, M.; Schiavone, N.; Guzman-Aranguez, A.; Giansanti, F.; Papucci, L.; Perez de Lara, M.J.; Singh, M.; Kaur, I.P. Correction to: Atorvastatin-Loaded Solid Lipid Nanoparticles as Eye Drops: Proposed Treatment Option for Age-Related Macular Degeneration (AMD). Drug Deliv. Transl. Res. 2020, 10, 1531. [Google Scholar] [CrossRef]
98. Mitra, R.N.; Gao, R.; Zheng, M.; Wu, M.J.; Voinov, M.A.; Smirnov, A.I.; Smirnova, T.I.; Wang, K.; Chavala, S.; Han, Z. Glycol Chitosan Engineered Autoregenerative Antioxidant Significantly Attenuates Pathological Damages in Models of Age-Related Macular Degeneration. ACS Nano 2017, 11, 4669–4685. [Google Scholar] [CrossRef]
99. Nagai, N.; Daigaku, R.; Motoyama, R.; Kaji, H.; Abe, T. Release of Ranibizumab Using a Porous Poly(Dimethylsiloxane) Capsule Suppressed Laser-Induced Choroidal Neovascularization via the Transscleral Route. J. Mater. Sci. Mater. Med. 2022, 34, 5. [Google Scholar] [CrossRef] [PubMed]
100. Qiu, F.; Meng, T.; Chen, Q.; Zhou, K.; Shao, Y.; Matlock, G.; Ma, X.; Wu, W.; Du, Y.; Wang, X.; et al. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. Mol. Pharm. 2019, 16, 1958–1970. [Google Scholar] [CrossRef]
101. Sun, Q.; Shen, Y.; Su, L.; Xu, X. Inhibition of Pathological Retinal Neovascularization by a Small Peptide Derived from Human Tissue-Type Plasminogen Kringle 2. Front. Pharmacol. 2020, 10, 1639. [Google Scholar] [CrossRef]
102. Ishibazawa, A.; Nagaoka, T.; Yokota, H.; Takahashi, A.; Omae, T.; Song, Y.S.; Takahashi, T.; Yoshida, A. Characteristics of Retinal Neovascularization in Proliferative Diabetic Retinopathy Imaged by Optical Coherence Tomography Angiography. Investig. Ophthalmol. Vis. Sci. 2016, 57, 6247–6255. [Google Scholar] [CrossRef]
103. Sacconi, R.; Fragiotta, S.; Sarraf, D.; Sadda, S.V.R.; Freund, K.B.; Parravano, M.; Corradetti, G.; Cabral, D.; Capuano, V.; Miere, A.; et al. Towards a Better Understanding of Non-Exudative Choroidal and Macular Neovascularization. Prog. Retin. Eye Res. 2023, 92, 101113. [Google Scholar] [CrossRef] [PubMed]
104. Fernandes, A.R.; dos Santos, T.; Granja, P.L.; Sanchez-Lopez, E.; Garcia, M.L.; Silva, A.M.; Souto, E.B. Permeability, Anti-Inflammatory and Anti-VEGF Profiles of Steroidal-Loaded Cationic Nanoemulsions in Retinal Pigment Epithelial Cells under Oxidative Stress. Int. J. Pharm. 2022, 617, 121615. [Google Scholar] [CrossRef] [PubMed]
105. García-Estrada, P.; García-Bon, M.A.; López-Naranjo, E.J.; Basaldúa-Pérez, D.N.; Santos, A.; Navarro-Partida, J. Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials. Pharmaceutics 2021, 13, 701. [Google Scholar] [CrossRef] [PubMed]
106. Gil-Martínez, M.; Santos-Ramos, P.; Fernández-Rodríguez, M.; Abraldes, M.J.; Rodríguez-Cid, M.J.; Santiago-Varela, M.; Fernández-Ferreiro, A.; Gómez-Ulla, F. Pharmacological Advances in the Treatment of Age-Related Macular Degeneration. Curr. Med. Chem. 2020, 27, 583–598. [Google Scholar] [CrossRef]
107. Ferrara, N.; Adamis, A.P. Ten Years of Anti-Vascular Endothelial Growth Factor Therapy. Nat. Rev. Drug Discov. 2016, 15, 385–403. [Google Scholar] [CrossRef]
108. Klettner, A.; Recber, M.; Roider, J. Comparison of the Efficacy of Aflibercept, Ranibizumab, and Bevacizumab in an RPE/Choroid Organ Culture. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252, 1593–1598. [Google Scholar] [CrossRef] [PubMed]
109. Oo, C.; Kalbag, S.S. Leveraging the Attributes of Biologics and Small Molecules, and Releasing the Bottlenecks: A New Wave of Revolution in Drug Development. Expert. Rev. Clin. Pharmacol. 2016, 9, 747–749. [Google Scholar] [CrossRef]
110. Li, J.; Mooney, D.J. Designing Hydrogels for Controlled Drug Delivery. Nat. Rev. Mater. 2016, 1, 16071. [Google Scholar] [CrossRef] [PubMed]
111. Galante, R.; Pinto, T.J.A.; Colaço, R.; Serro, A.P. Sterilization of Hydrogels for Biomedical Applications: A Review. J. Biomed. Mater. Res. B Appl. Biomater. 2018, 106, 2472–2492. [Google Scholar] [CrossRef]
112. Bordbar-Khiabani, A.; Gasik, M. Smart Hydrogels for Advanced Drug Delivery Systems. Int. J. Mol. Sci. 2022, 23, 3665. [Google Scholar] [CrossRef]
113. Osswald, C.R.; Kang-Mieler, J.J. Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System. Curr. Eye Res. 2016, 41, 1216–1222. [Google Scholar] [CrossRef] [PubMed]
114. Osswald, C.R.; Guthrie, M.J.; Avila, A.; Valio, J.A.; Mieler, W.F.; Kang-Mieler, J.J. In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System. Curr. Eye Res. 2017, 42, 1293–1301. [Google Scholar] [CrossRef] [PubMed]
115. Hu, C.C.; Chiu, Y.C.; Chaw, J.R.; Chen, C.F.; Liu, H.W. Thermo-Responsive Hydrogel as an Anti-VEGF Drug Delivery System to Inhibit Retinal Angiogenesis in Rex Rabbits. Technol. Health Care 2019, 27, S153–S163. [Google Scholar] [CrossRef]
116. Xue, K.; Zhao, X.; Zhang, Z.; Qiu, B.; Tan, Q.S.W.; Ong, K.H.; Liu, Z.; Parikh, B.H.; Barathi, V.A.; Yu, W.; et al. Sustained Delivery of Anti-VEGFs from Thermogel Depots Inhibits Angiogenesis without the Need for Multiple Injections. Biomater. Sci. 2019, 7, 4603–4614. [Google Scholar] [CrossRef]
117. Liu, W.; Lee, B.S.; Mieler, W.F.; Kang-Mieler, J.J. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro. Curr. Eye Res. 2019, 44, 264–274. [Google Scholar] [CrossRef]
118. Liu, W.; Tawakol, A.P.; Rudeen, K.M.; Mieler, W.F.; Kang-Mieler, J.J. Treatment Efficacy and Biocompatibility of a Biodegradable Aflibercept-Loaded Microsphere-Hydrogel Drug Delivery System. Transl. Vis. Sci. Technol. 2020, 9, 13. [Google Scholar] [CrossRef]
119. Fan, W.; Li, S.; Tao, J.; Yu, C.; Sun, M.; Xie, Z.; Wu, X.; Ge, L.; Wu, Y.; Liu, Y. Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration. J. Biomed. Nanotechnol. 2022, 18, 277–287. [Google Scholar] [CrossRef] [PubMed]
120. Li, J.; Tian, Q.; Sun, H.; Zhang, Y.; Yang, X.; Kaur, P.; Wang, R.; Fang, Y.; Yan, H.; Du, X.; et al. A Novel, Liposome-Loaded, Injectable Hydrogel for Enhanced Treatment of Choroidal Neovascularization by Sub-Tenon’s Injection. Mater. Today Nano 2022, 20, 100264. [Google Scholar] [CrossRef]
121. Tanetsugu, Y.; Tagami, T.; Terukina, T.; Ogawa, T.; Ohta, M.; Ozeki, T. Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(Lactic-Co-Glycolic Acid) Biodegradable Polymer-Based Microparticles as a Platform. Biol. Pharm. Bull. 2017, 40, 145–150. [Google Scholar] [CrossRef]
122. Sousa, F.; Cruz, A.; Fonte, P.; Pinto, I.M.; Neves-Petersen, M.T.; Sarmento, B. A New Paradigm for Antiangiogenic Therapy through Controlled Release of Bevacizumab from PLGA Nanoparticles. Sci. Rep. 2017, 7, 3736. [Google Scholar] [CrossRef]
123. Sousa, F.; Cruz, A.; Pinto, I.M.; Sarmento, B. Nanoparticles Provide Long-Term Stability of Bevacizumab Preserving Its Antiangiogenic Activity. Acta Biomater. 2018, 78, 285–295. [Google Scholar] [CrossRef]
124. Zhang, X.P.; Sun, J.G.; Yao, J.; Shan, K.; Liu, B.H.; Yao, M.D.; Ge, H.M.; Jiang, Q.; Zhao, C.; Yan, B. Effect of Nanoencapsulation Using Poly (Lactide-Co-Glycolide) (PLGA) on Anti-Angiogenic Activity of Bevacizumab for Ocular Angiogenesis Therapy. Biomed. Pharmacother. 2018, 107, 1056–1063. [Google Scholar] [CrossRef] [PubMed]
125. Kelly, S.J.; Hirani, A.; Shahidadpury, V.; Solanki, A.; Halasz, K.; Gupta, S.V.; Madow, B.; Sutariya, V. Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro Model: A Preliminary Report. Biomedicines 2018, 6, 92. [Google Scholar] [CrossRef] [PubMed]
126. Yan, J.; Peng, X.; Cai, Y.; Cong, W. Development of Facile Drug Delivery Platform of Ranibizumab Fabricated PLGA-PEGylated Magnetic Nanoparticles for Age-Related Macular Degeneration Therapy. J. Photochem. Photobiol. B 2018, 183, 133–136. [Google Scholar] [CrossRef] [PubMed]
127. Liu, J.; Zhang, X.; Li, G.; Xu, F.; Li, S.; Teng, L.; Li, Y.; Sun, F. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications. Int. J. Nanomed. 2019, 14, 8819–8834. [Google Scholar] [CrossRef]
128. Heljak, M.K.; Swieszkowski, W. In Silico Model of Bevacizumab Sustained Release from Intravitreal Administrated PLGA Drug-Loaded Microspheres. Mater. Lett. 2021, 307, 131080. [Google Scholar] [CrossRef]
129. Liu, J.; Li, S.; Li, G.; Li, X.; Yu, C.; Fu, Z.; Li, X.; Teng, L.; Li, Y.; Sun, F. Highly Bioactive, Bevacizumab-Loaded, Sustained-Release PLGA/PCADK Microspheres for Intravitreal Therapy in Ocular Diseases. Int. J. Pharm. 2019, 563, 228–236. [Google Scholar] [CrossRef]
130. Tsujinaka, H.; Fu, J.; Shen, J.; Yu, Y.; Hafiz, Z.; Kays, J.; McKenzie, D.; Cardona, D.; Culp, D.; Peterson, W.; et al. Sustained Treatment of Retinal Vascular Diseases with Self-Aggregating Sunitinib Microparticles. Nat. Commun. 2020, 11, 694. [Google Scholar] [CrossRef] [PubMed]
131. Luo, L.; Yang, J.; Oh, Y.; Hartsock, M.J.; Xia, S.; Kim, Y.C.; Ding, Z.; Meng, T.; Eberhart, C.G.; Ensign, L.M.; et al. Controlled Release of Corticosteroid with Biodegradable Nanoparticles for Treating Experimental Autoimmune Uveitis. J. Control. Release 2019, 296, 68–80. [Google Scholar] [CrossRef] [PubMed]
132. Cai, W.; Chen, Q.; Shen, T.; Yang, Q.; Hu, W.; Zhao, P.; Yu, J. Intravenous Anti-VEGF Agents with RGD Peptide-Targeted Core Cross-Linked Star (CCS) Polymers Modified with Indocyanine Green for Imaging and Treatment of Laser-Induced Choroidal Neovascularization. Biomater. Sci. 2020, 8, 4481–4491. [Google Scholar] [CrossRef]
133. Luis de Redín, I.; Boiero, C.; Martínez-Ohárriz, M.C.; Agüeros, M.; Ramos, R.; Peñuelas, I.; Allemandi, D.; Llabot, J.M.; Irache, J.M. Human Serum Albumin Nanoparticles for Ocular Delivery of Bevacizumab. Int. J. Pharm. 2018, 541, 214–223. [Google Scholar] [CrossRef]
134. Luis de Redín, I.; Boiero, C.; Recalde, S.; Agüeros, M.; Allemandi, D.; Llabot, J.M.; García-Layana, A.; Irache, J.M. In Vivo Effect of Bevacizumab-Loaded Albumin Nanoparticles in the Treatment of Corneal Neovascularization. Exp. Eye Res. 2019, 185, 107697. [Google Scholar] [CrossRef]
135. Llabot, J.M.; Luis de Redin, I.; Agüeros, M.; Dávila Caballero, M.J.; Boiero, C.; Irache, J.M.; Allemandi, D. In Vitro Characterization of New Stabilizing Albumin Nanoparticles as a Potential Topical Drug Delivery System in the Treatment of Corneal Neovascularization (CNV). J. Drug Deliv. Sci. Technol. 2019, 52, 379–385. [Google Scholar] [CrossRef]
136. Pandit, J.; Sultana, Y.; Aqil, M. Chitosan-Coated PLGA Nanoparticles of Bevacizumab as Novel Drug Delivery to Target Retina: Optimization, Characterization, and in Vitro Toxicity Evaluation. Artif. Cells Nanomed. Biotechnol. 2017, 45, 1397–1407. [Google Scholar] [CrossRef]
137. Ugurlu, N.; Aşık, M.D.; Çakmak, H.B.; Tuncer, S.; Turk, M.; Çagıl, N.; Denkbas, E.B. Transscleral Delivery of Bevacizumab-Loaded Chitosan Nanoparticles. J. Biomed. Nanotechnol. 2019, 15, 830–838. [Google Scholar] [CrossRef]
138. Savin, C.L.; Popa, M.; Delaite, C.; Costuleanu, M.; Costin, D.; Peptu, C.A. Chitosan Grafted-Poly(Ethylene Glycol) Methacrylate Nanoparticles as Carrier for Controlled Release of Bevacizumab. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 98, 843–860. [Google Scholar] [CrossRef] [PubMed]
139. Jiang, P.; Chaparro, F.J.; Cuddington, C.T.; Palmer, A.F.; Ohr, M.P.; Lannutti, J.J.; Swindle-Reilly, K.E. Injectable Biodegradable Bi-Layered Capsule for Sustained Delivery of Bevacizumab in Treating Wet Age-Related Macular Degeneration. J. Control. Release 2020, 320, 442–456. [Google Scholar] [CrossRef] [PubMed]
140. Jiang, P.; Jacobs, K.M.; Ohr, M.P.; Swindle-Reilly, K.E. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab. Mol. Pharm. 2020, 17, 2570–2584. [Google Scholar] [CrossRef]
141. Chaharband, F.; Daftarian, N.; Kanavi, M.R.; Varshochian, R.; Hajiramezanali, M.; Norouzi, P.; Arefian, E.; Atyabi, F.; Dinarvand, R. Trimethyl Chitosan-Hyaluronic Acid Nano-Polyplexes for Intravitreal VEGFR-2 SiRNA Delivery: Formulation and in Vivo Efficacy Evaluation. Nanomedicine 2020, 26, 102181. [Google Scholar] [CrossRef]
142. Formica, M.L.; Legeay, S.; Bejaud, J.; Montich, G.G.; Ullio Gamboa, G.V.; Benoit, J.P.; Palma, S.D. Novel Hybrid Lipid Nanocapsules Loaded with a Therapeutic Monoclonal Antibody—Bevacizumab—And Triamcinolone Acetonide for Combined Therapy in Neovascular Ocular Pathologies. Mater. Sci. Eng. C Mater. Biol. Appl. 2021, 119, 111398. [Google Scholar] [CrossRef]
143. Mu, H.; Wang, Y.; Chu, Y.; Jiang, Y.; Hua, H.; Chu, L.; Wang, K.; Wang, A.; Liu, W.; Li, Y.; et al. Multivesicular Liposomes for Sustained Release of Bevacizumab in Treating Laser-Induced Choroidal Neovascularization. Drug Deliv. 2018, 25, 1372–1383. [Google Scholar] [CrossRef] [PubMed]
144. Karumanchi, D.K.; Skrypai, Y.; Thomas, A.; Gaillard, E.R. Rational Design of Liposomes for Sustained Release Drug Delivery of Bevacizumab to Treat Ocular Angiogenesis. J. Drug Deliv. Sci. Technol. 2018, 47, 275–282. [Google Scholar] [CrossRef]
145. de Cristo Soares Alves, A.; Lavayen, V.; Figueiró, F.; Dallemole, D.R.; de Fraga Dias, A.; Cé, R.; Battastini, A.M.O.; Guterres, S.S.; Pohlmann, A.R. Chitosan-Coated Lipid-Core Nanocapsules Functionalized with Gold-III and Bevacizumab Induced In Vitro Cytotoxicity against C6 Cell Line and In Vivo Potent Antiangiogenic Activity. Pharm. Res. 2020, 37, 91. [Google Scholar] [CrossRef] [PubMed]
146. Jiang, P.; Choi, A.; Swindle-Reilly, K.E. Controlled Release of Anti-VEGF by Redox-Responsive Polydopamine Nanoparticles. Nanoscale 2020, 12, 17298–17311. [Google Scholar] [CrossRef] [PubMed]
147. Webber, A.L.; Sharwood, P. Practical Use and Prescription of Ocular Medications in Children and Infants. Clin. Exp. Optom. 2021, 104, 385–395. [Google Scholar] [CrossRef]
148. Sheybani, N.D.; Yang, H. Pediatric Ocular Nanomedicines: Challenges and Opportunities. Chin. Chem. Lett. 2017, 28, 1817–1821. [Google Scholar] [CrossRef]
149. Sunita, M.; Manisha, S.; Sanjeev, M.K.; Ravi, K.S.; Aarzoo, J.; Ajai, A. Anatomical and Clinical Characteristics of Paediatric and Adult Eyes. Natl. J. Clin. Anat. 2021, 10, 5. [Google Scholar] [CrossRef]
150. Mudgil, P.; Borchman, D.; Ramasubramanian, A. Insights into Tear Film Stability from Babies and Young Adults: A Study of Human Meibum Lipid Conformation and Rheology. Int. J. Mol. Sci. 2018, 19, 3502. [Google Scholar] [CrossRef]
151. Chidi-Egboka, N.C.; Briggs, N.E.; Jalbert, I.; Golebiowski, B. The Ocular Surface in Children: A Review of Current Knowledge and Meta-Analysis of Tear Film Stability and Tear Secretion in Children. Ocul. Surf. 2019, 17, 28–39. [Google Scholar] [CrossRef]
152. Mutlu, F.M.; Sarici, S.U. Treatment of Retinopathy of Prematurity: A Review of Conventional and Promising New Therapeutic Options. Int. J. Ophthalmol. 2013, 6, 228–236. [Google Scholar] [CrossRef]
153. Mukherjee, P.; Bhattacharya, R.; Wang, P.; Wang, L.; Basu, S.; Nagy, J.A.; Atala, A.; Mukhopadhyay, D.; Soker, S. Antiangiogenic Properties of Gold Nanoparticles. Clin. Cancer Res. 2005, 11, 3530–3534. [Google Scholar] [CrossRef]
154. Saeed, B.A.; Lim, V.; Yusof, N.A.; Khor, K.Z.; Rahman, H.S.; Samad, N.A. Antiangiogenic Properties of Nanoparticles: A Systematic Review. Int. J. Nanomed. 2019, 14, 5135–5146. [Google Scholar] [CrossRef]
155. Kim, J.H.; Kim, M.H.; Jo, D.H.; Yu, Y.S.; Lee, T.G.; Kim, J.H. The Inhibition of Retinal Neovascularization by Gold Nanoparticles via Suppression of VEGFR-2 Activation. Biomaterials 2011, 32, 1865–1871. [Google Scholar] [CrossRef] [PubMed]
156. Kolosnjaj-Tabi, J.; Volatron, J.; Gazeau, F. Basic Principles of in Vivo Distribution, Toxicity, and Degradation of Prospective Inorganic Nanoparticles for Imaging. In Design and Applications of Nanoparticles in Biomedical Imaging; Springer: Cham, Switzerland, 2016; pp. 9–41. [Google Scholar] [CrossRef]
157. Radomska, A.; Leszczyszyn, J.; Radomski, M.W. The Nanopharmacology and Nanotoxicology of Nanomaterials: New Opportunities and Challenges. Adv. Clin. Exp. Med. 2016, 25, 151–162. [Google Scholar] [CrossRef] [PubMed]
158. Higbee-Dempsey, E.M.; Amirshaghaghi, A.; Case, M.J.; Bouché, M.; Kim, J.; Cormode, D.P.; Tsourkas, A. Biodegradable Gold Nanoclusters with Improved Excretion Due to PH-Triggered Hydrophobic-to-Hydrophilic Transition. J. Am. Chem. Soc. 2020, 142, 7783–7794. [Google Scholar] [CrossRef] [PubMed]
159. Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering Precision Nanoparticles for Drug Delivery. Nat. Rev. Drug Discov. 2020, 20, 101–124. [Google Scholar] [CrossRef] [PubMed]
160. Bohley, M.; Dillinger, A.E.; Schweda, F.; Ohlmann, A.; Braunger, B.M.; Tamm, E.R.; Goepferich, A. A Single Intravenous Injection of Cyclosporin A-Loaded Lipid Nanocapsules Prevents Retinopathy of Prematurity. Sci. Adv. 2022, 8. [Google Scholar] [CrossRef]
161. Li, Q.; Weng, J.; Wong, S.N.; Thomas Lee, W.Y.; Chow, S.F. Nanoparticulate Drug Delivery to the Retina. Mol. Pharm. 2021, 18, 506–521. [Google Scholar] [CrossRef]
162. Bertrand, N.; Leroux, J.C. The Journey of a Drug-Carrier in the Body: An Anatomo-Physiological Perspective. J. Control. Release 2012, 161, 152–163. [Google Scholar] [CrossRef]
163. Hagigit, T.; Abdulrazik, M.; Valamanesh, F.; Behar-Cohen, F.; Benita, S. Ocular Antisense Oligonucleotide Delivery by Cationic Nanoemulsion for Improved Treatment of Ocular Neovascularization: An in-Vivo Study in Rats and Mice. J. Control. Release 2012, 160, 225–231. [Google Scholar] [CrossRef]
164. Hagigit, T.; Nassar, T.; Behar-Cohen, F.; Lambert, G.; Benita, S. The Influence of Cationic Lipid Type on In-Vitro Release Kinetic Profiles of Antisense Oligonucleotide from Cationic Nanoemulsions. Eur. J. Pharm. Biopharm. 2008, 70, 248–259. [Google Scholar] [CrossRef]
165. Hagigit, T.; Abdulrazik, M.; Orucov, F.; Valamanesh, F.; Lambert, M.; Lambert, G.; Behar-Cohen, F.; Benita, S. Topical and Intravitreous Administration of Cationic Nanoemulsions to Deliver Antisense Oligonucleotides Directed towards VEGF KDR Receptors to the Eye. J. Control. Release 2010, 145, 297–305. [Google Scholar] [CrossRef] [PubMed]
166. Xu, W.; Wu, Y.; Hu, Z.; Sun, L.; Dou, G.; Zhang, Z.; Wang, H.; Guo, C.; Wang, Y. Exosomes from Microglia Attenuate Photoreceptor Injury and Neovascularization in an Animal Model of Retinopathy of Prematurity. Mol. Ther. Nucleic Acids 2019, 16, 778–790. [Google Scholar] [CrossRef] [PubMed]
167. Moisseiev, E.; Anderson, J.D.; Oltjen, S.; Goswami, M.; Zawadzki, R.J.; Nolta, J.A.; Park, S.S. Protective Effect of Intravitreal Administration of Exosomes Derived from Mesenchymal Stem Cells on Retinal Ischemia. Curr. Eye Res. 2017, 42, 1358–1367. [Google Scholar] [CrossRef] [PubMed]
168. Ebneter, A.; Kokona, D.; Schneider, N.; Zinkernagel, M.S. Microglia Activation and Recruitment of Circulating Macrophages During Ischemic Experimental Branch Retinal Vein Occlusion. Investig. Ophthalmol. Vis. Sci. 2017, 58, 944–953. [Google Scholar] [CrossRef]
169. Deliyanti, D.; Talia, D.M.; Zhu, T.; Maxwell, M.J.; Agrotis, A.; Jerome, J.R.; Hargreaves, E.M.; Gerondakis, S.; Hibbs, M.L.; Mackay, F.; et al. Foxp3+ Tregs Are Recruited to the Retina to Repair Pathological Angiogenesis. Nat. Commun. 2017, 8, 748. [Google Scholar] [CrossRef]
170. Muffat, J.; Li, Y.; Yuan, B.; Mitalipova, M.; Omer, A.; Corcoran, S.; Bakiasi, G.; Tsai, L.H.; Aubourg, P.; Ransohoff, R.M.; et al. Efficient Derivation of Microglia-like Cells from Human Pluripotent Stem Cells. Nat. Med. 2016, 22, 1358–1367. [Google Scholar] [CrossRef]
171. Wang, Z.; Liu, A.; Zhang, H.; Wang, M.; Tang, Q.; Huang, Y.; Wang, L. Inhibition of Retinal Neovascularization by VEGF SiRNA Delivered via Bioreducible Lipid-like Nanoparticles. Graefes Arch. Clin. Exp. Ophthalmol. 2020, 258, 2407–2418. [Google Scholar] [CrossRef]
172. Singerman, L. Combination Therapy Using the Small Interfering RNA Bevasiranib. Retina 2009, 29, S49–S50. [Google Scholar] [CrossRef]
173. Jiang, Y.; Huo, S.; Hardie, J.; Liang, X.J.; Rotello, V.M. Progress and Perspective of Inorganic Nanoparticle-Based SiRNA Delivery Systems. Expert Opin. Drug Deliv. 2016, 13, 547–559. [Google Scholar] [CrossRef]
174. Huang, K.; Lin, Z.; Ge, Y.; Chen, X.; Pan, Y.; Lv, Z.; Sun, X.; Yu, H.; Chen, J.; Yao, Q. Immunomodulation of MiRNA-223-Based Nanoplatform for Targeted Therapy in Retinopathy of Prematurity. J. Control. Release 2022, 350, 789–802. [Google Scholar] [CrossRef] [PubMed]
175. Sung, M.S.; Moon, M.J.; Thomas, R.G.; Kim, S.Y.; Lee, J.S.; Jeong, Y.Y.; Park, I.K.; Park, S.W. Intravitreal Injection of Liposomes Loaded with a Histone Deacetylase Inhibitor Promotes Retinal Ganglion Cell Survival in a Mouse Model of Optic Nerve Crush. Int. J. Mol. Sci. 2020, 21, 9297. [Google Scholar] [CrossRef] [PubMed]
176. Wang, T.; Li, Y.; Guo, M.; Dong, X.; Liao, M.; Du, M.; Wang, X.; Yin, H.; Yan, H. Exosome-Mediated Delivery of the Neuroprotective Peptide PACAP38 Promotes Retinal Ganglion Cell Survival and Axon Regeneration in Rats With Traumatic Optic Neuropathy. Front. Cell Dev. Biol. 2021, 9, 659783. [Google Scholar] [CrossRef] [PubMed]
177. Mezu-Ndubuisi, O.J.; Wang, Y.; Schoephoerster, J.; Falero-Perez, J.; Zaitoun, I.S.; Sheibani, N.; Gong, S. Intravitreal Delivery of VEGF-A165-Loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity. Curr. Eye Res. 2019, 44, 275–286. [Google Scholar] [CrossRef] [PubMed]
178. Hong, E.H.; Shin, Y.U.; Cho, H. Retinopathy of Prematurity: A Review of Epidemiology and Current Treatment Strategies. Clin. Exp. Pediatr. 2022, 65, 115–126. [Google Scholar] [CrossRef]
179. Desjarlais, M.; Rivera, J.C.; Lahaie, I.; Cagnone, G.; Wirt, M.; Omri, S.; Chemtob, S. MicroRNA Expression Profile in Retina and Choroid in Oxygen-Induced Retinopathy Model. PLoS ONE 2019, 14, e0218282. [Google Scholar] [CrossRef]
180. Lee, S.S.; Hughes, P.; Ross, A.D.; Robinson, M.R. Biodegradable Implants for Sustained Drug Release in the Eye. Pharm. Res. 2010, 27, 2043–2053. [Google Scholar] [CrossRef]
181. Castro-Navarro, V.; Cervera-Taulet, E.; Navarro-Palop, C.; Monferrer-Adsuara, C.; Hernández-Bel, L.; Montero-Hernández, J. Intravitreal Dexamethasone Implant Ozurdex® in Naïve and Refractory Patients with Different Subtypes of Diabetic Macular Edema. BMC Ophthalmol. 2019, 19, 15. [Google Scholar] [CrossRef]
182. Kuno, N.; Fujii, S. Biodegradable Intraocular Therapies for Retinal Disorders: Progress to Date. Drugs Aging 2010, 27, 117–134. [Google Scholar] [CrossRef]
183. Khiev, D.; Mohamed, Z.A.; Vichare, R.; Paulson, R.; Bhatia, S.; Mohapatra, S.; Lobo, G.P.; Valapala, M.; Kerur, N.; Passaglia, C.L.; et al. Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery. Nanomaterials 2021, 11, 173. [Google Scholar] [CrossRef]
184. Wong, J.G.; Chang, A.; Guymer, R.H.; Wickremasinghe, S.; Reilly, E.; Bell, N.; Vantipalli, S.; Moshfeghi, A.A.; Goldstein, M.H. Phase 1 Study of an Intravitreal Axitinib Hydrogel-Based Implant for the Treatment of Neovascular Age-Related Macular Degeneration (NAMD). Investig. Ophthalmol. Vis. Sci. 2021, 62, 218. [Google Scholar]
185. Alshaikh, R.A.; Waeber, C.; Ryan, K.B. Polymer Based Sustained Drug Delivery to the Ocular Posterior Segment: Barriers and Future Opportunities for the Treatment of Neovascular Pathologies. Adv. Drug Deliv. Rev. 2022, 187, 114342. [Google Scholar] [CrossRef] [PubMed]
186. Vinores, S.A. Pegaptanib in the Treatment of Wet, Age-Related Macular Degeneration. Int. J. Nanomed. 2006, 1, 263–268. [Google Scholar]
187. Yang, M.; Peterson, W.M.; Yu, Y.; Kays, J.; Cardona, D.; Culp, D.; Gilger, B.C.; Cleland, J. GB-102 for Wet AMD: A Novel Injectable Formulation That Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months. Investig. Ophthalmol. Vis. Sci. 2016, 57, 5037. [Google Scholar]
188. Cheng, Y.; Burda, C. 2.01—Nanoparticles for Photodynamic Therapy. In Comprehensive Nanoscience and Technology; Andrews, D.L., Scholes, G.D., Wiederrecht, G.P., Eds.; Academic Press: Amsterdam, The Netherlands, 2011; pp. 1–28. ISBN 978-0-12-374396-1. [Google Scholar]
189. Rodrigues, G.A.; Lutz, D.; Shen, J.; Yuan, X.; Shen, H.; Cunningham, J.; Rivers, H.M. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation. Pharm. Res. 2018, 35, 245. [Google Scholar] [CrossRef] [PubMed]
190. Doukas, J.; Mahesh, S.; Umeda, N.; Kachi, S.; Akiyama, H.; Yokoi, K.; Cao, J.; Chen, Z.; Dellamary, L.; Tam, B.; et al. Topical Administration of a Multi-Targeted Kinase Inhibitor Suppresses Choroidal Neovascularization and Retinal Edema. J. Cell. Physiol. 2008, 216, 29–37. [Google Scholar] [CrossRef]
191. Yafai, Y.; Yang, X.M.; Niemeyer, M.; Nishiwaki, A.; Lange, J.; Wiedemann, P.; King, A.G.; Yasukawa, T.; Eichler, W. Anti-Angiogenic Effects of the Receptor Tyrosine Kinase Inhibitor, Pazopanib, on Choroidal Neovascularization in Rats. Eur. J. Pharmacol. 2011, 666, 12–18. [Google Scholar] [CrossRef]
192. Adams, C.M.; Anderson, K.; Artman, G.; Bizec, J.C.; Cepeda, R.; Elliott, J.; Fassbender, E.; Ghosh, M.; Hanks, S.; Hardegger, L.A.; et al. The Discovery of N-(1-Methyl-5-(Trifluoromethyl)-1H-Pyrazol-3-Yl)-5-((6- ((Methylamino)Methyl)Pyrimidin-4-Yl)Oxy)-1H-Indole-1-Carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. J. Med. Chem. 2018, 61, 1622–1635. [Google Scholar] [CrossRef] [PubMed]
193. Zernii, E.Y.; Baksheeva, V.E.; Iomdina, E.N.; Averina, O.A.; Permyakov, S.E.; Philippov, P.P.; Zamyatnin, A.A.; Senin, I.I. Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches. CNS Neurol. Disord. Drug Targets 2016, 15, 267–291. [Google Scholar] [CrossRef]
194. Owen, G.R.; Brooks, A.C.; James, O.; Robertson, S.M. A Novel in Vivo Rabbit Model That Mimics Human Dosing to Determine the Distribution of Antibiotics in Ocular Tissues. J. Ocul. Pharmacol. Ther. 2007, 23, 335–342. [Google Scholar] [CrossRef]
195. Shen, J.; Durairaj, C.; Lin, T.; Liu, Y.; Burke, J. Ocular Pharmacokinetics of Intravitreally Administered Brimonidine and Dexamethasone in Animal Models with and without Blood-Retinal Barrier Breakdown. Investig. Ophthalmol. Vis. Sci. 2014, 55, 1056–1066. [Google Scholar] [CrossRef]
196. Kang-Mieler, J.J.; Rudeen, K.M.; Liu, W.; Mieler, W.F. Advances in Ocular Drug Delivery Systems. Eye 2020, 34, 1371–1379. [Google Scholar] [CrossRef] [PubMed]
197. Paunovska, K.; Loughrey, D.; Dahlman, J.E. Drug Delivery Systems for RNA Therapeutics. Nat. Rev. Genet. 2022, 23, 265–280. [Google Scholar] [CrossRef] [PubMed]
198. Jahangirian, H.; Lemraski, E.G.; Webster, T.J.; Rafiee-Moghaddam, R.; Abdollahi, Y. A Review of Drug Delivery Systems Based on Nanotechnology and Green Chemistry: Green Nanomedicine. Int. J. Nanomed. 2017, 12, 2957–2978. [Google Scholar] [CrossRef] [PubMed]
199. Sung, Y.K.; Kim, S.W. Recent Advances in Polymeric Drug Delivery Systems. Biomater. Res. 2020, 24, 12. [Google Scholar] [CrossRef] [PubMed]